Navigation Links
Pharmaxis to Apply to Market Bronchitol in Australia
Date:2/13/2008

SYDNEY, Australia, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it will apply for Australian marketing approval of Bronchitol for patients with bronchiectasis, following a meeting with the Australian Therapeutic Goods Administration (TGA).

Bronchitol is being developed as a twice daily therapy for people with the incurable lung condition Bronchiectasis. The meeting with the TGA on 12 February was arranged following the successful completion of a Phase III clinical study of Bronchitol in the second half of 2007. The trial demonstrated a significant improvement in the quality of life for patients treated with Bronchitol, and a significant difference in their mucus clearance.

Pharmaxis will submit its marketing authorisation application following the conclusion of the ongoing safety component of the Phase III trial - an optional 12 month extension to determine the safety of long-term Bronchitol treatment. This component of the trial has had a high participation rate and a low withdrawal rate, and will complete mid-year. Pharmaxis will file the marketing application during the third quarter of 2008.

"We are delighted that our discussions with the TGA have provided a path forward for bringing Bronchitol to market in Australia," said Pharmaxis Chief Executive Officer Alan Robertson.

"More than 20,000 Australians suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in over 20 years -- addressing an important medical need."

Bronchiectasis is an incurable, degenerative and chronic lung condition that makes breathing difficult through excessive mucus build up in the lungs. Pharmaxis has the only product in Phase III clinical trials for bronchiectasis anywhere in the world.

Over 600,000 patients worldwide suffer from bronchiectasis. Total U.S. medical care expenditure is US$13,000 per bronchiectasis patient, doub
'/>"/>

SOURCE Pharmaxis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. Pharmaxis Appoints Portuguese Distributor for Aridol
5. Pharmaxis Aridol Gains First Asian Approval
6. Pharmaxis Investor Conference Call
7. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
10. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
11. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Halozyme Therapeutics, ... Update Conference Call for the second quarter 2015 on ... PT. Dr. Helen Torley , president and chief ... date post-market, Halozyme will release financial results for the ... webcast live through the "Investors" section of Halozyme,s corporate ...
(Date:8/3/2015)... ... 03, 2015 , ... The synthetic rubber industry is recognized ... as ethylbenzene, a precursor to styrene, used to make styrene-butadiene resins, styrene butadiene ... production of tyres and other components. Thus, growth in the automotive industry is ...
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the compact, ... of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an ... and maintenance-free solution for a broad range of vacuum filtration applications. , Featuring ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2
... March 13 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; OTC: MGIFF), ... results for the three and nine months ended,January 31, ... DeMesa, M.D., President & CEO of MIGENIX stated, "With ... halfway through our,fourth quarter, we are looking forward to ...
... ARNA ) announced today that the company is scheduled to,provide ... programs, at two upcoming investor conferences:, -- Cowen ... Wednesday, March 19, 2008 at 8:45 a.m. Eastern Time (5:45 ... Marriott Copley Place in Boston, Massachusetts ...
... REINACH, Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced ... 2007., 2007 highlights, Major pipeline progress:, ... in cSSSI,achieves its pre-specified primary endpoint, as did the ... for intravenous iclaprim in,cSSSI initiated, - First patients ...
Cached Biology Technology:MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 16Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Miami (UM) students have received prestigious Graduate Research Fellowships ... work on coral reefs. Rachel Silverstein and Nitzan Soffer ... work in the laboratory of Dr. Andrew Baker, an ... Fisheries at UMs Rosenstiel School of Marine and Atmospheric ...
... OSU researchers received grants totaling more than $240,000 last ... Science and Technology under its Oklahoma Applied Research Support ... potential for producing a commercially successful product, according to ... Oklahoma businesses, universities and non-profit organizations to accelerate the ...
... Rochelle, NY -- As the Nobel Foundation recognizes the ... DNA, the newly formed Rosalind Franklin Society celebrates the ... made this breakthrough possible. Although Franklin was ... late Francis Crick, the late Maurice Wilkins, and James ...
Cached Biology News:Everything's coming up corals 2Everything's coming up corals 3OCAST funds OSU projects with commercial viability 2
... Product Goat polyclonal to Cholesterol ... Reactivity / Specificity Cross-reacts with ... Background Information Cholesterol oxidases exist ... oxidases and are implicated in bacterial pathogenesis. ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: